The DOI matches its Crossref record; 169 of the 169 references it cites were found in a registry or an index.
Treatment-Resistant Schizophrenia
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090
(1976) · Medical Entomology and Zoology · Cited by 8,899
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
Clozapine for the Treatment-Resistant Schizophrenic: A Double-blind Comparison With Chlorpromazine
Kane, J. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800330013001 · Cited by 4,156
Green, M. F., Kern, R. S., Braff, D. L., & Mintz, J. (2000) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033430 · Cited by 2,999
Remission in Schizophrenia: Proposed Criteria and Rationale for Consensus
Andreasen, N. C., Carpenter, W. T., Kane, J. M., Lasser, R. A., Marder, S. R., & Weinberger, D. R. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.3.441 · Cited by 2,343
Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis
Leucht, S., Corves, C., Arbter, D., Engel, R. R., Li, C., & Davis, J. M. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61764-x · Cited by 1,930
Keefe, R. (2004) · Schizophrenia Research · doi:10.1016/j.schres.2003.09.011 · Cited by 1,573
Discovering the Neural Basis of Human Social Anxiety: A Diagnostic and Therapeutic Imperative
Charney, D. S. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.1.1 · Cited by 1,428
Meltzer, H. Y. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.1.82 · Cited by 1,393
LEUCHT, S., KANE, J., KISSLING, W., HAMANN, J., ETSCHEL, E., & ENGEL, R. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.04.008 · Cited by 1,226
Honea, R., Crow, T. J., Passingham, D., & Mackay, C. E. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.12.2233 · Cited by 1,157
Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia
Saykin, A. J. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950020048005 · Cited by 1,086
Geddes, J., Freemantle, N., Harrison, P., & Bebbington, P. (2000) · BMJ · doi:10.1136/bmj.321.7273.1371 · Cited by 1,062
A Meta-analysis of the Efficacy of Second-Generation Antipsychotics
Davis, J. M., Chen, N., & Glick, I. D. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.6.553 · Cited by 1,034
Recovery from psychotic illness: A 15- and 25-year international follow-up study
Harrison, G., Hopper, K., Craig, T., Laska, E., Siegel, C., Wanderling, J., Dube, K. C., Ganev, K., Giel, R., Der Heiden, W. A., et al. (2001) · British Journal of Psychiatry · doi:10.1192/bjp.178.6.506 · Cited by 1,030
McEvoy, J. P., Lieberman, J. A., Stroup, T. S., Davis, S. M., Meltzer, H. Y., Rosenheck, R. A., Swartz, M. S., Perkins, D. O., Keefe, R. S. E., Davis, C. E., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.4.600 · Cited by 1,018
One hundred years of schizophrenia: a meta-analysis of the outcome literature
(1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.10.1409 · Cited by 762
The Schizophrenia Patient Outcomes Research Team (PORT): Updated Treatment Recommendations 2003
Lehman, A. F., Kreyenbuhl, J., Buchanan, R. W., Dickerson, F. B., Dixon, L. B., Goldberg, R., Green-Paden, L. D., Tenhula, W. N., Boerescu, D., Tek, C., et al. (2004) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a007071 · Cited by 757
Elevated Striatal Dopamine Function Linked to Prodromal Signs of Schizophrenia
Howes, O. D., Montgomery, A. J., Asselin, M.-C., Murray, R. M., Valli, I., Tabraham, P., Bramon-Bosch, E., Valmaggia, L., Johns, L., Broome, M., et al. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2008.514 · Cited by 744
Practice Guideline for the Treatment of Patients With Schizophrenia Second Edition
(2007) · APA Practice Guidelines for the Treatment of Psychiatric Disorders: Comprehensive Guidelines and Guideline Watches · doi:10.1176/appi.books.9780890423363.45859 · Cited by 737
Sensky, T., Turkington, D., Kingdon, D., Scott, J. L., Scott, J., Siddle, R., O'Carroll, M., & Barnes, T. R. E. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.2.165 · Cited by 693
Stroup, T. S., McEvoy, J. P., Swartz, M. S., Byerly, M. J., Glick, I. D., Canive, J. M., McGee, M. F., Simpson, G. M., Stevens, M. C., & Lieberman, J. A. (2003) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a006986 · Cited by 636
Chakos, M., Lieberman, J., Hoffman, E., Bradford, D., & Sheitman, B. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.4.518 · Cited by 631
Hoffman, R. E., Hawkins, K. A., Gueorguieva, R., Boutros, N. N., Rachid, F., Carroll, K., & Krystal, J. H. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.1.49 · Cited by 517
Treatment-Resistant Schizophrenia - The Role of Clozapine
Meltzer, H. Y. (1997) · Current Medical Research and Opinion · doi:10.1185/03007999709113338 · Cited by 491
Persistent Negative Symptoms in Schizophrenia: An Overview
Buchanan, R. W. (2007) · Schizophrenia Bulletin · doi:10.1093/schbul/sbl057 · Cited by 443
Lewis, S. W., Barnes, T. R. E., Davies, L., Murray, R. M., Dunn, G., Hayhurst, K. P., Markwick, A., Lloyd, H., & Jones, P. B. (2005) · Schizophrenia Bulletin · doi:10.1093/schbul/sbj067 · Cited by 422
Volavka, J., Czobor, P., Sheitman, B., Lindenmayer, J.-P., Citrome, L., McEvoy, J. P., Cooper, T. B., Chakos, M., & Lieberman, J. A. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.2.255 · Cited by 407
Wahlbeck, K., Cheine, M., Essali, A., & Adams, C. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.7.990 · Cited by 357
Management of treatment resistance in schizophrenia
Conley, R. R., & Kelly, D. L. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01271-9 · Cited by 352
Anchoring the BPRS: an aid to improved reliability.
Woerner, M. G., Mannuzza, S., & Jm, K. (1988) · PubMed · Cited by 341
Association between clozapine response and allelic variation in 5-HT2A receptor gene
Arranz, M. J., Collier, D. A., Sodhi, M., Ball, D., Roberts, G. W., Sham, P., Kerwin, R., Price, J., & Roberts, G. W. (1995) · The Lancet · doi:10.1016/s0140-6736(95)92168-0 · Cited by 333
Clozapine versus typical neuroleptic medication for schizophrenia
Essali, A., Al-Haj Haasan, N., Li, C., & Rathbone, J. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000059.pub2 · Cited by 329
Five factor model of schizophrenia: replication across samples
Lindenmayer, J. (1995) · Schizophrenia Research · doi:10.1016/0920-9964(94)00041-6 · Cited by 328
Weinberger, D. R. (1980) · Archives of General Psychiatry · doi:10.1001/archpsyc.1980.01780140013001 · Cited by 323
The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6
Lin, A., Kenis, G., Bignotti, S., Tura, G.-J.-B., De Jong, R., Bosmans, E., Pioli, R., Altamura, C., Scharpé, S., & Maes, M. (1998) · Schizophrenia Research · doi:10.1016/s0920-9964(98)00034-6 · Cited by 321
The Texas Medication Algorithm Project Antipsychotic Algorithm for Schizophrenia: 2006 Update
Moore, T. A., & Buchanan, R. W. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n1115 · Cited by 288
Suicidal risk during treatment with clozapine: a meta-analysis
Hennen, J., & Baldessarini, R. J. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2004.05.015 · Cited by 287
Bondolfi, G., Dufour, H., Patris, M., May, J. P., Billeter, U., Eap, C. B., & Baumann, P. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.4.499 · Cited by 283
Clozapine alone versus clozapine and risperidone with refractory schizophrenia
Honer, W. G., Thornton, A. E., Chen, E. Y. H., Chan, R. C. K., Wong, J. O. Y., Bergmann, A., Falkai, P., Pomarol-Clotet, E., McKenna, P. J., Stip, E., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053222 · Cited by 277
Cognitive Behavior Therapy for Schizophrenia
Turkington, D., Kingdon, D., & Weiden, P. J. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.3.365 · Cited by 275
Hoffman, R. E., Gueorguieva, R., Hawkins, K. A., Varanko, M., Boutros, N. N., Wu, Y.-T., Carroll, K., & Krystal, J. H. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.03.041 · Cited by 272
Waddington, J. L., Youssef, H. A., & Kinsella, A. (1998) · British Journal of Psychiatry · doi:10.1192/bjp.173.4.325 · Cited by 267
Schulte, P. F. J. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342070-00001 · Cited by 264
Quetiapine versus other atypical antipsychotics for schizophrenia
Komossa, K., Rummel-Kluge, C., Schmid, F., Hunger, H., Schwarz, S., Srisurapanont, M., Kissling, W., & Leucht, S. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006625.pub2 · Cited by 260
Shiloh, R., Zemishlany, Z., Aizenberg, D., Radwan, M., Schwartz, B., Dorfman-Etrog, P., Modai, I., Khaikin, M., & Weizman, A. (1997) · British Journal of Psychiatry · doi:10.1192/bjp.171.6.569 · Cited by 260
Freudenreich, O., & Goff, D. C. (2002) · Acta Psychiatrica Scandinavica · doi:10.1034/j.1600-0447.2002.01331.x · Cited by 259
Caudate nuclei volumes in schizophrenic patients treated with typical antipsychotics or clozapine
Chakos, M., Lieberman, J., Alvir, J., Bilder, R., & Ashtari, M. (1995) · The Lancet · doi:10.1016/s0140-6736(95)90441-7 · Cited by 250
Olanzapine Compared With Chlorpromazine in Treatment-Resistant Schizophrenia
Conley, R. R., Tamminga, C. A., Bartko, J. J., Richardson, C., Peszke, M., Lingle, J., Hegerty, J., Love, R., Gounaris, C., & Zaremba, S. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.7.914 · Cited by 245
At Issue: Defining Treatment Refractoriness in Schizophrenia
Brenner, H. D., Dencker, S. J., Goldstein, M. J., Hubbard, J. W., Keegan, D. L., Kruger, G., Kulhanek, F., Liberman, R. P., Malm, U., & Midha, K. K. (1990) · Schizophrenia Bulletin · doi:10.1093/schbul/16.4.551 · Cited by 242
The Texas Medication Algorithm Project Antipsychotic Algorithm for Schizophrenia: 2003 Update
Miller, A. L., Hall, C. S., Buchanan, R. W., Buckley, P. F., Chiles, J. A., Conley, R. R., Crismon, M. L., Ereshefsky, L., Essock, S. M., Finnerty, M., et al. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0408 · Cited by 234
Josiassen, R. C., Joseph, A., Kohegyi, E., Stokes, S., Dadvand, M., Paing, W. W., & Shaughnessy, R. A. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.1.130 · Cited by 233
d-Serine Added to Clozapine for the Treatment of Schizophrenia
Tsai, G. E., Yang, P., Chung, L.-C., Tsai, I.-C., Tsai, C.-W., & Coyle, J. T. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.11.1822 · Cited by 227
Kumra, S., Kranzler, H., Gerbino-Rosen, G., Kester, H. M., DeThomas, C., Kafantaris, V., Correll, C. U., & Kane, J. M. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.04.043 · Cited by 223
Functional Assessment in Rehabilitation
Wallace, C. J. (1986) · Schizophrenia Bulletin · doi:10.1093/schbul/12.4.604 · Cited by 222
Arranz, M. J., Munro, J., Owen, M. J., Spurlock, G., Sham, P. C., Zhao, J., Kirov, G., Collier, D. A., & Kerwin, R. W. (1998) · Molecular Psychiatry · doi:10.1038/sj.mp.4000348 · Cited by 220
Plasma clozapine concentrations predict clinical response in treatment-resistant schizophrenia.
Potkin, S. G., Bera, R., Gulasekaram, B., Costa, J., Hayes, S., Jin, Y., Richmond, G., Carreon, D., Sitanggan, K., & Gerber, B. (1994) · PubMed · Cited by 206
Tollefson, G. D., Birkett, M. A., Kiesler, G. M., & Wood, A. J. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(00)01026-x · Cited by 202
Lamotrigine in treatment-resistant schizophrenia: a randomized placebo-controlled crossover trial
Tiihonen, J., Hallikainen, T., Ryynänen, O.-P., Repo-Tiihonen, E., Kotilainen, I., Eronen, M., Toivonen, P., Wahlbeck, K., & Putkonen, A. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00524-9 · Cited by 191
Yagcioglu, A. E. A., Akdede, B. B. K., Turgut, T. I., Tümüklü, M., Yazici, M. K., Alptekin, K., Ertugrul, A., Jayathilake, K., Gögüs, A., Tunca, Z., et al. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0109 · Cited by 185
Age at onset and gender of schizophrenic patients in relation to neuroleptic resistance
(1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.4.475 · Cited by 184
Cortical folding abnormalities in schizophrenia patients with resistant auditory hallucinations
Cachia, A., Paillère-Martinot, M.-L., Galinowski, A., Januel, D., de Beaurepaire, R., Bellivier, F., Artiges, E., Andoh, J., Bartrés-Faz, D., Duchesnay, E., et al. (2008) · NeuroImage · doi:10.1016/j.neuroimage.2007.08.049 · Cited by 184
D-cycloserine added to clozapine for patients with schizophrenia
(1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.12.1628 · Cited by 182
Improvement of Schizophrenic Patients Treated With Des-Tyr1]-γ-endorphin (DTγE)
Verhoeven, W. M. A. (1979) · Archives of General Psychiatry · doi:10.1001/archpsyc.1979.01780030060005 · Cited by 180
Meltzer, H. Y., Bobo, W. V., Roy, A., Jayathilake, K., Aygun, C., Elif, E. A., Yagcioglu, A., & Small, J. G. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0214 · Cited by 176
Placebo-Controlled Trial of Glycine Added to Clozapine in Schizophrenia
Evins, A. E., Fitzgerald, S. M., Wine, L., Rosselli, R., & Goff, D. C. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.5.826 · Cited by 172
Cognitive behavioral psychotherapy for schizophrenia: a review of recent empirical studies
Dickerson, F. B. (2000) · Schizophrenia Research · doi:10.1016/s0920-9964(99)00153-x · Cited by 169
Psychobiologic Correlates of Treatment Response in Schizophrenia
Lieberman, J. (1996) · Neuropsychopharmacology · doi:10.1016/0893-133x(95)00200-w · Cited by 169
Valmaggia, L. R., van der Gaag, M., Tarrier, N., Pijnenborg, M., & Slooff, C. J. (2005) · British Journal of Psychiatry · doi:10.1192/bjp.186.4.324 · Cited by 163
Lee, S., Kim, W. B., Chung, Y.-C., Jung, K.-H., Bahk, W., Jun, T.-Y., Kim, K., George, M. S., & Chae, J. (2004) · Neuroscience Letters · doi:10.1016/j.neulet.2004.11.048 · Cited by 159
Relationships Between Obsessive-Compulsive Symptomatology and Severity of Psychosis in Schizophrenia
Cunill, R., Castells, X., & Simeon, D. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.07r03618 · Cited by 156
Does the Addition of a Second Antipsychotic Drug Improve Clozapine Treatment?
Barbui, C., Signoretti, A., Mule, S., Boso, M., & Cipriani, A. (2008) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn030 · Cited by 153
Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia
Bitter, I., Dossenbach, M. R. K., Brook, S., Feldman, P. D., Metcalfe, S., Gagiano, C. A., Füredi, J., Bartkó, G., Janka, Z., Bánki, C. M., et al. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2003.09.033 · Cited by 147
Psychopathology of Schizophrenia: Initial Validation of a 5-Factor Model
Lindenmayer, J., Bernstein-Hyman, R., Grochowski, S., & Bark, N. M. (2010) · Psychopathology · doi:10.1159/000284896 · Cited by 142
Childhood-onset schizophrenia: brain MRI rescan after 2 years of clozapine maintenance treatment
Frazier, J. A., Giedd, J. N., Kaysen, D. L., Albus, K. E., Hamburger, S., Alaghband‐Rad, J., Lenane, M., McKenna, K., Breier, A. F., & Rapoport, J. L. (1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.4.564 · Cited by 141
The natural history and pathophysiology of treatment resistant schizophrenia
Sheitman, B. B., & Lieberman, J. A. (1998) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(97)00052-6 · Cited by 140
Convulsive Therapy in Schizophrenia?
Fink, M., & Sackeïm, H. A. (1996) · Schizophrenia Bulletin · doi:10.1093/schbul/22.1.27 · Cited by 140
Effect of Clozapine and Adjunctive High-Dose Glycine in Treatment-Resistant Schizophrenia
Potkin, S. G., Jin, Y., Bunney, B. G., COSTA, J. F., & Gulasekaram, B. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.1.145 · Cited by 139
When Symptoms Persist: Clozapine Augmentation Strategies
Buckley, P., Miller, A. L., Olsen, J., Garver, D., Miller, D. D., & Csernansky, J. G. (2001) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a006901 · Cited by 139
Pinto, A., Pia, S. L., Mennella, R., Giorgio, D., & DeSimone, L. (1999) · Psychiatric Services · doi:10.1176/ps.50.7.901 · Cited by 137
Analysis of a structural polymorphism in the 5-HT2A receptor and clinical response to clozapine
Arranz, M. J., Collier, D. A., Munro, J., Sham, P. C., Kirov, G., Sodhi, M., Roberts, G. W., Price, J., & Kerwin, R. W. (1996) · Neuroscience Letters · doi:10.1016/0304-3940(96)13094-9 · Cited by 136
Treatment Refractory Schizophrenia
Lindenmayer, J. (2000) · Psychiatric Quarterly · doi:10.1023/a:1004640408501 · Cited by 135
Transcranial magnetic stimulation for auditory hallucinations in schizophrenia
McIntosh, A. M., Semple, D. M., Tasker, K., Harrison, L. K., Owens, D. G. C., Johnstone, E. C., & Ebmeier, K. P. (2004) · Psychiatry Research · doi:10.1016/j.psychres.2004.03.005 · Cited by 133
Scheepers, F. E., de Wied, C. C., Pol, H. E. H., van de Flier, W., van der Linden, J. A., & Kahn, R. S. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(00)00172-x · Cited by 131
Kane, J. M., Meltzer, H. Y., Carson, W. H., et al. (2007) · PubMed · Cited by 128
Serotonin-6 receptor variant (C267T) and clinical response to clozapine
Yu, Y. W. ‐., Tsai, S., Lin, C., Hsu, C., Yang, K., & Hong, C. (1999) · Neuroreport · doi:10.1097/00001756-199904260-00014 · Cited by 126
Revising polypharmacy to a single antipsychotic regimen for patients with chronic schizophrenia
Suzuki, T., Uchida, H., Tanaka, K. F., Nomura, K., Takano, H., Tanabe, A., Watanabe, K., Yagi, G., & Kashima, H. (2004) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145703004012 · Cited by 126
Ciapparelli, A., Dell’Osso, L., di Poggio, A. B., Carmassi, C., Cecconi, D., Fenzi, M., Chiavacci, M. C., Bottai, M., Ramacciotti, C., & Cassano, G. B. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0416 · Cited by 123
Mouaffak, F., Tranulis, C., Gourévitch, R., Poirier, M. F., Douki, S., Oli, J.-P., Löo, H., & Gourion, D. (2006) · Clinical Neuropharmacology · doi:10.1097/00002826-200601000-00009 · Cited by 121
Electroconvulsive therapy for the treatment of clozapine nonresponders suffering from schizophrenia
Kho, K. H., Blansjaar, B. A., de Vries, S., Babuskova, D., Zwinderman, A. H., & Linszen, D. H. (2004) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-004-0517-y · Cited by 117
Plasma clozapine concentrations as a predictor of clinical response: a follow-up study.
Miller, D. D., Fleming, F. J., Holman, T. L., & Perry, P. J. (1994) · PubMed · Cited by 115
D1 receptor alleles predict PET metabolic correlates of clinical response to clozapine
Potkin, S. G., Basile, V. S., Jin, Y., Masellis, M., Badri, F., Keator, D., Wu, J. C., Alva, G., Carreon, D., Bunney, W. E., et al. (2003) · Molecular Psychiatry · doi:10.1038/sj.mp.4001191 · Cited by 113
Henderson, D. C., Kunkel, L., Nguyen, D. D., Borba, C. P. C., Daley, T. B., Louie, P. M., Freudenreich, O., Cather, C., Evins, A. E., & GOFF, D. C. (2005) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2005.00612.x · Cited by 113
Do you see what I see? Interpretations of intentional movement in schizophrenia
Russell, T. A., Reynaud, E., Herba, C. M., Morris, R. G., & Corcoran, R. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.10.002 · Cited by 112
Polypharmacy in Patients With Schizophrenia
McCue, R. E., Waheed, R., & Urcuyo, L. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0902 · Cited by 110
Munro, J., Matthíasson, P., Osborne, S., Travis, M. J., Purcell, S., Cobb, A., Launer, M. A., Beer, M. D., & Kerwin, R. (2004) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2004.00356.x · Cited by 109
Elliot, M. G., & Bilsker, D. (1995) · The Canadian Journal of Psychiatry · doi:10.1177/070674379504000208 · Cited by 105
Zoccali, R. A., Muscatello, M. R. A., Cedro, C., Neri, P., Torre, D. L., Spina, E., Rosa, A. E. D., & Meduri, M. (2004) · International Clinical Psychopharmacology · doi:10.1097/00004850-200403000-00003 · Cited by 104
Tuunainen, A., Wahlbeck, K., & Gilbody, S. M. (2002) · Schizophrenia Research · doi:10.1016/s0920-9964(01)00212-2 · Cited by 103
Small, J. G., Klapper, M. H., Malloy, F. W., & Steadman, T. M. (2003) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000084026.22282.5f · Cited by 102
Naber, D., Riedel, M. J., Klimke, A., Vorbach, E.-U., Lambert, M., Kühn, K. ‐., Bender, S., Bandelow, B., Lemmer, W., Moritz, S., et al. (2005) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2004.00486.x · Cited by 102
Rosa, M. O., & Gattaz, W. F. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n1009 · Cited by 98
Topiramate Add-On in Treatment-Resistant Schizophrenia
Tiihonen, J., Halonen, P. M., Wahlbeck, K., Repo‐Tiihonen, E., Hyvärinen, S., Eronen, M., Putkonen, H., Takala, P., Mehtonen, O. ‐., Puck, M., et al. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0808 · Cited by 98
Prefrontal sulcal prominence is inversely related to response to clozapine in schizophrenia
Friedman, L., Knutson, L., Shurell, M., et al. (1991) · Biological Psychiatry · doi:10.1016/0006-3223(91)90053-o · Cited by 98
Arango, C., Breier, A. F., McMahon, R. P., Carpenter, W. T., & Buchanan, R. W. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.8.1421 · Cited by 96
Barbui, C., Nos, M., Mazzi, M. A., Thornicroft, G., Schene, A. H., Becker, T. M., Bindman, J. P., Leese, M., Helm, H., Koeter, M. W. J., et al. (2006) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000224785.68040.43 · Cited by 91
Transcranial Magnetic Stimulation of Left Auditory Cortex in Patients With Schizophrenia
d’Alfonso, A. A. L., Aleman, A., Kessels, R. P. C., SCHOUTEN, E. A. M., Postma, A., van der Linden, J. A., Cahn, W., Greene, Y. M., de Haan, E. H. F., & Kahn, R. S. (2002) · Journal of Neuropsychiatry · doi:10.1176/jnp.14.1.77 · Cited by 90
Prediction of outcome in first-episode schizophrenia.
Ja, L. (1993) · PubMed · Cited by 88
Managing patients with “treatment‐resistant” schizophrenia
Pantelis, C., & Lambert, T. (2003) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2003.tb05310.x · Cited by 85
Ciapparelli, A., Dell’Osso, L., Pini, S., Chiavacci, M. C., Fenzi, M., & Cassano, G. B. (2000) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v61n0502 · Cited by 82
Refractory schizophrenia and atypical antipsychotics
Taylor, D. M., Taylor, D. M., & Duncan-McConnell, D. (2000) · Journal of Psychopharmacology · doi:10.1177/026988110001400411 · Cited by 78
Risperidone versus clozapine in treatment-resistant schizophrenia: A randomized pilot study
Wahlbeck, K., Cheine, M. V., Tuisku, K., Ahokas, A., Joffe, G., & Rimón, R. (2000) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(00)00118-4 · Cited by 76
Effect of Clozapine on Caudate Nucleus Volume in Relation to Symptoms of Schizophrenia
Scheepers, F. E., Wied, C. C. G., Pol, H. E. H., & Kahn, R. S. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.4.644 · Cited by 75
Cerebral metabolic changes induced by clozapine in schizophrenia and related to clinical improvement
Molina, V., Gispert, J. D., Reig, S., Sanz, J., Pascau, J., Santos, A., Desco, M., & Palomo, T. (2004) · Psychopharmacology · doi:10.1007/s00213-004-1981-9 · Cited by 75
Relationship between catechol‐O‐methyltransferase polymorphism and treatment‐resistant schizophrenia
Inada, T., Nakamura, A., & Iijima, Y. (2003) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.20023 · Cited by 74
Moncrieff, J. (2003) · The British Journal of Psychiatry · doi:10.1192/bjp.183.2.161 · Cited by 74
Effects of Atypical Antipsychotics on the Syndromal Profile in Treatment-Resistant Schizophrenia
Lindenmayer, J., Czobor, P., Volavka, J., et al. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0416 · Cited by 73
Association study of GSK3 gene polymorphisms with schizophrenia and clozapine response
de Souza, R. P., Romano‐Silva, M. A., Lieberman, J. A., Meltzer, H. Y., Wong, A. H. C., & Kennedy, J. L. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1193-9 · Cited by 71
The evolving definition of treatment resistance.
Peuskens, J. (1999) · PubMed · Cited by 66
Efficacy and tolerability of ziprasidone in patients with treatment-resistant schizophrenia
Kane, J. M., Khanna, S., Rajadhyaksha, S., & Giller, E. L. (2005) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000182114.65134.81 · Cited by 65
Vaddadi, K. S., Gilleard, C. J., Mindham, R. H. S., & Butler, R. (1986) · Psychopharmacology · doi:10.1007/bf00180839 · Cited by 60
Commentary: Defining Treatment Refractoriness in Schizophrenia
Meltzer, H. Y. (1990) · Schizophrenia Bulletin · doi:10.1093/schbul/16.4.563 · Cited by 60
Dose Response and Atypical Antipsychotics in Schizophrenia
Kinon, B. J., AHL, J. S. B., Stauffer, V. L., Hill, A. L., & Buckley, P. F. (2004) · CNS Drugs · doi:10.2165/00023210-200418090-00005 · Cited by 59
Allopurinol augmentation for poorly responsive schizophrenia
Lara, D. R., Brunstein, M. G., Ghisolfi, E. S., Lobato, M. I. R., Belmonte-de-Abreu, P. S., & Souza, D. O. (2001) · International Clinical Psychopharmacology · doi:10.1097/00004850-200107000-00008 · Cited by 59
Olanzapine in Refractory Schizophrenia After Failure of Typical or Atypical Antipsychotic Treatment
Lindenmayer, J., Czobor, P., Volavka, J., Lieberman, J. A., Citrome, L., Sheitman, B., Chakos, M., & McEvoy, J. P. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n1011 · Cited by 59
Switching From Clozapine to Olanzapine in Treatment-Refractory Schizophrenia
Henderson, D. C., Nasrallah, R. A., & GOFF, D. C. (1998) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v59n1105 · Cited by 57
Validation of Polypharmacy Process Measures in Inpatient Schizophrenia Care
Janssen, B., Weinmann, S., Berger, T., & Gäebel, W. (2004) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a007117 · Cited by 57
Molina, V., Andrée, R. M., Castejón, M. J. P., Zamora, M. L. C., Álvaro, P. C., Delgado, J. L. C., & Vila, F. J. R. (1997) · Psychiatry Research Neuroimaging · doi:10.1016/s0925-4927(97)00057-7 · Cited by 56
Comprehensive Care of Schizophrenia: A Textbook of Clinical Management
Puzantian, T. (2001) · Annals of Pharmacotherapy · doi:10.1345/1542-6270(2001)35<1678a:ccosat>2.0.co;2 · Cited by 55
Dossenbach, M. R. K., Beuzen, J. N., Avnon, M., Belmaker, R. H., Elizur, A., Mark, M., Munitz, H., Schneidman, M., Shoshani, D., Kratky, P., et al. (2000) · Clinical Therapeutics · doi:10.1016/s0149-2918(00)80082-x · Cited by 54
Lawrie, S. M., Abukmeil, S. S., Chiswick, A., Egan, V., Santosh, C., & Best, J. J. K. (1997) · Schizophrenia Research · doi:10.1016/s0920-9964(97)00019-4 · Cited by 50
Clozapine-resistant schizophrenia: A positive approach
Williams, L., Newton, G., Roberts, K., Finlayson, S., & Brabbins, C. (2002) · The British Journal of Psychiatry · doi:10.1192/bjp.181.3.184 · Cited by 50
Romano, F., & Elkis, H. (1996) · Jornal Brasileiro de Psiquiatria · Cited by 49
Self-citationManagement of Treatment Resistant Schizophrenia Unresponsive to Clozapine
Barnes, T. R. E., McEvedy, C., & Nelson, H. E. (1996) · The British Journal of Psychiatry · doi:10.1192/s0007125000298590 · Cited by 47
Therapeutic studies in “therapy resistant” schizophrenic patients
Itil, T. M., Keskiner, A., & Fink, M. (1966) · Comprehensive Psychiatry · doi:10.1016/s0010-440x(66)80028-7 · Cited by 46
Efficacy of electroconvulsive therapy in treatment-resistant schizophrenia: a prospective open trial
Tang, W. K., & Ungvari, G. S. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(02)00354-8 · Cited by 45
Clinical aspects of super-refractory schizophrenia: a 6-month cohort observational study
Neto, J. H., & Elkis, H. (2007) · Brazilian Journal of Psychiatry · doi:10.1590/s1516-44462007000300007 · Cited by 44
Self-citationZiprasidone Augmentation of Clozapine in 11 Patients
Kaye, N. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0215b · Cited by 44
McMahon, R. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00387-6 · Cited by 43
de Castro, A. P. W., & Elkis, H. (2007) · Brazilian Journal of Psychiatry · doi:10.1590/s1516-44462007000300004 · Cited by 43
Self-citationMolina, V., Reig, S., Sanz, J., Palomo, T., Benito, C., Sarramea, F., Pascau, J., Sánchez, J. C., Martín‐Loeches, M., Muñoz, F., et al. (2007) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2007.08.017 · Cited by 43
Switching Clozapine Responders to Olanzapine
Littrell, K. H., Johnson, C. G., Hilligoss, N. M., Peabody, C. D., & Littrell, S. H. (2000) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v61n1204 · Cited by 43
Predictors and markers of clozapine response
Chung, C., & Remington, G. J. (2005) · Psychopharmacology · doi:10.1007/s00213-005-2174-x · Cited by 41
Lithium Combined with Haloperidol in Schizophrenic Patients
Lerner, Y., Mintzer, Y., & Schestatzky, M. (1988) · The British Journal of Psychiatry · doi:10.1192/bjp.153.3.359 · Cited by 40
Some biological correlates of drug resistance in schizophrenia: A multidimensional approach
Altamura, A. C., Bassetti, R., Cattaneo, E., & Vismara, S. (2005) · The World Journal of Biological Psychiatry · doi:10.1080/15622970510030027 · Cited by 39
Lawrie, S. M., Ingle, G. T., Santosh, C., Rogers, A. C., Rimmington, J. E., Naidu, K. P., Best, J. J. K., O’Carroll, R. E., Goodwin, G. M., Ebmeier, K. P., et al. (1995) · The British Journal of Psychiatry · doi:10.1192/bjp.167.2.202 · Cited by 39
Association between regional brain volumes and clozapine response in schizophrenia
Lauriello, J., Mathalon, D. H., Rosenbloom, M. J., Sullivan, E. V., Faustman, W. O., Ringo, D. L., Lim, K. O., & Adolf Pfefferbaum, A. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(97)00491-5 · Cited by 38
Molina, V., Andrée, R. M., Mj, P. C., Labrador, R. G., Ferre, F., Delgado, J. L. C., & Vila, F. J. R. (1997) · Schizophrenia Research · doi:10.1016/s0920-9964(96)00115-6 · Cited by 37
Predictors of response to high dose antipsychotics in chronic schizophrenics
Little, K. Y., Gay, T. L., & Vore, M. (1989) · Psychiatry Research · doi:10.1016/0165-1781(89)90166-2 · Cited by 34
Treatment resistance in schizophrenia
Barnes, T. R. E., & Dursun, S. M. (2005) · Psychiatry · doi:10.1383/psyt.2005.4.11.68 · Cited by 32
Molina, V., Tamayo, P., Montes, C., de Luxan, A., Martin, C., Rivas, N., Sancho, C., & Domínguez‐Gil, A. (2008) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2007.12.028 · Cited by 31
The psychopharmacology of schizophrenia
Fleischhacker, W. W. (1999) · Current Opinion in Psychiatry · doi:10.1097/00001504-199901000-00017 · Cited by 27
The psychopathological factors of refractory schizophrenia
Alves, T. M., Pereira, J. C. R., & Elkis, H. (2005) · Brazilian Journal of Psychiatry · doi:10.1590/s1516-44462005000200007 · Cited by 26
Self-citationPredictors of response in a sample of treatment-resistant psychotic patients on clozapine
Ciapparelli, A., Ducci, F., Carmassi, C., Carlini, M., Paggini, R., Catena, M., Bottai, M., & Dell’Osso, L. (2004) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-004-0511-4 · Cited by 22
Management of treatment resistant schizophrenia
Jones, S., & Castle, D. J. (2006) · African Journal of Psychiatry · doi:10.4314/ajpsy.v9i1.30202 · Cited by 22
Adjunctive Carbamazepine or Lithium Carbonate in Therapy-Resistant Chronic Schizophrenia
Simhandl, C., Meszaros, K., Denk, E., Thau, K., & Topitz, A. (1996) · The Canadian Journal of Psychiatry · doi:10.1177/070674379604100513 · Cited by 22
Lal, S., Thavundayil, J., Nair, N. P. V., Annable, L., Kin, N. M. K. N. Y., Gabriel, A., & Schwartz, G. J. (2006) · Journal of Psychiatry and Neuroscience · doi:10.1139/jpn.0631 · Cited by 21
Augmentation of clozapine partial responders with conventional antipsychotics
Rajarethinam, R., Gilani, S., Tancer, M. E., & DeQuardo, J. R. (2002) · Schizophrenia Research · doi:10.1016/s0920-9964(02)00293-1 · Cited by 20
Management of Treatment Refractory Schizophrenia
Morrison, D. P. (1996) · The British Journal of Psychiatry · doi:10.1192/s0007125000298577 · Cited by 19
Treatment-refractory schizophrenia
Buckley, P. F., & Shendarkar, N. (2005) · Current Opinion in Psychiatry · doi:10.1097/00001504-200503000-00010 · Cited by 18
Chen, R. Y. L., Chen, E. Y. H., & Ho, W. Y. (2000) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s004060070036 · Cited by 18
da Costa, D. A. (1997) · Schizophrenia Research · doi:10.1016/s0920-9964(97)00120-5 · Cited by 17
Hobbs, M. J. (2015) · Elsevier eBooks · doi:10.1016/b978-0-08-097086-8.27025-6 · Cited by 11
Treatment of Chronic Schizophrenia
Johnson, D. A. W. (1977) · Drugs · doi:10.2165/00003495-197714040-00004 · Cited by 11
Treatment resistance in schizophrenia
Psychiatry, G. (1999) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(99)90099-8 · Cited by 10
Clinical Trials in Schizophrenia with Results for the Real World
Perkins, D. O. (2006) · CNS Spectrums · doi:10.1017/s1092852900026638 · Cited by 8
Cited by
Jauhar, S., Johnstone, M., & McKenna, P. J. (2022) · The Lancet · doi:10.1016/s0140-6736(21)01730-x · Cited by 996
Treatment resistant schizophrenia: Clinical, biological, and therapeutic perspectives
Nucifora, F. C., Woznica, E., Lee, B. J., Cascella, N., & Sawa, A. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.08.016 · Cited by 304
Sample size requirements for the internal validation of psychiatric scales
Rouquette, A., & Falissard, B. (2011) · International Journal of Methods in Psychiatric Research · doi:10.1002/mpr.352 · Cited by 296
Zhou, S.-F., Wang, B., Yang, L.-P., & Liu, J.-P. (2010) · Drug Metabolism Reviews · doi:10.3109/03602530903286476 · Cited by 262
Quetiapine versus other atypical antipsychotics for schizophrenia
Komossa, K., Rummel-Kluge, C., Schmid, F., Hunger, H., Schwarz, S., Srisurapanont, M., Kissling, W., & Leucht, S. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006625.pub2 · Cited by 260
Metadata
- Authors
- Elkis, H.
- Venue
- Psychiatric Clinics of North America
- Publisher
- Elsevier BV
- Published
- 2007-09
- Volume
- 30
- Issue
- 3
- Pages
- 511-533
- ISSN
- 0193-953X (ISSN-L)
- OpenAlex
- W2005342508
- Cited by
- 338
- References
- 169
- FWCI
- 7.46
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.